You've been getting UTIs more often than you can explain. Sex has become uncomfortable in a way you didn't expect. There's a dryness and occasional burning that didn't exist in your 30s. You mention it at your annual appointment and get a pamphlet about hydration.
What you likely have is GSM — genitourinary syndrome of menopause. It's one of the most common consequences of estrogen decline, it affects the vagina, vulva, and urinary tract all at once, and it's treated far less often than it should be. Partly because women don't raise it. Partly because clinicians don't ask.
What's actually happening in your body
Estrogen maintains the thickness, elasticity, and lubrication of vaginal tissue. It also keeps vaginal pH acidic (around 3.5–4.5), which protects against bacterial overgrowth and UTIs.
When estrogen drops in perimenopause and menopause, vaginal tissue thins and becomes more fragile. Collagen in the vaginal walls decreases. Lubrication during arousal slows. pH rises toward alkaline, which disrupts the lactobacillus-dominant microbiome and makes the urinary tract more vulnerable to infection. This is the cascade behind GSM — and why it affects the bladder and urethra, not just the vagina.
A 2023 NAMS position statement confirmed that GSM is distinct from the older term "vulvovaginal atrophy" because it better captures the urinary symptoms: urgency, frequency, increased UTI susceptibility, and painful urination that many women experience alongside the vaginal changes. The statement also confirmed that local vaginal estrogen therapy has minimal systemic absorption and is considered safe for most women, including many with a history of breast cancer, in consultation with their oncologist.
What helps — and what the evidence says
The treatment hierarchy for GSM is well-established. Local vaginal estrogen is the most effective option, with multiple RCTs and decades of safety data supporting it. It works differently from systemic HRT — very little is absorbed into the bloodstream, which means the risks associated with systemic hormones largely don't apply.
For women who prefer non-hormonal options, or for whom even local estrogen is not appropriate, there are good alternatives. This is genuinely complex territory, and the right choice depends on individual history — which is worth a real conversation with your OB-GYN.
Local vaginal estrogen: Available as a cream, tablet, ring, or soft insert. All forms have strong efficacy evidence. Studies show improvement in vaginal dryness, discomfort, and UTI frequency within 8–12 weeks. Systemic absorption is minimal at standard doses. ACOG and NAMS both recommend it broadly for GSM, including for many women with early-stage hormone-receptor positive breast cancer (with oncology input).
Vaginal DHEA (prasterone/Intrarosa): A non-estrogen option that the body converts locally to both estrogen and testosterone. FDA-approved for GSM. Particularly useful for women who want to avoid any form of estrogen.
Ospemifene (Osphena): An oral SERM that acts like estrogen in vaginal tissue but not the uterus or breast. FDA-approved. Works for women who can't or don't want to use topical treatment. Requires a prescription.
Vaginal moisturizers: Not the same as lubricants. Used regularly (every 2–3 days), not just during sex, vaginal moisturizers restore tissue hydration over time. Look for products with hyaluronic acid or polycarbophil. Evidence supports them as a non-hormonal alternative, though they're less effective than local estrogen for moderate-severe symptoms.
Lubricants during sex: Water-based or silicone-based are appropriate. Avoid warming or scented lubricants, which increase irritation in already-sensitized tissue. Consistent use reduces micro-tears and associated discomfort significantly.
What to say to your doctor
- "I've been experiencing vaginal dryness and I'm getting more UTIs — I think it could be GSM" — naming the condition helps move the appointment forward
- "I'd like to know about local vaginal estrogen options" — distinguish clearly that you're asking about local, not systemic HRT
- "Are there non-hormonal prescription options if I decide I don't want to use estrogen?" — ospemifene and vaginal DHEA are both worth discussing
- If you've had breast cancer: "Can you speak to my oncologist about whether local vaginal estrogen is appropriate for me?" — many oncologists now support it at standard doses
A note from our medical advisors
GSM is underdiagnosed and undertreated because women are embarrassed to raise it and many clinicians don't screen for it. Bring it up directly. If you're not getting answers, ask for a referral to a menopause specialist or a urogynecologist. Recurring UTIs in a postmenopausal woman that aren't responding to standard antibiotics are often GSM-driven — treating the underlying cause, not just the infection, is the right approach.
References
- The Menopause Society. Genitourinary Syndrome of Menopause Position Statement. Menopause. 2023. NAMS Position Statements
- Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and NAMS. Menopause. 2014;21(10):1063–1068. PubMed 25160739
- Santoro N, Epperson CN, Mathews SB. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. PubMed 26316239
- ACOG Practice Bulletin #141. Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216. PubMed 24463691